Atlas Trials

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Clinical trial NCT03570983 · UNKNOWN

Trial details

NCT number
NCT03570983
Sponsor
Swedish Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2018-09-05
Primary completion
2024-06-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.